Glenmark Pharmaceuticals Ltd (GLENMARK) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Glenmark reported consolidated revenue of 32,644 million in Q1 FY26, a 0.6% YoY growth.
- India formulations business showed strong secondary sales growth of 15.1% as per IQVIA, outperforming the market.
- North America business saw 8.9% QoQ growth driven by injectable product launches and partnered products.
- Europe business declined 4% YoY but anticipates returning to double-digit growth from Q2 FY26 onwards.
- Emerging Markets recorded 0.2% YoY growth, impacted by lower seasonal demand in some Latin American markets, but other regions grew 9%.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.